Star Therapeutics Raises $200 Million in New Funding
The firm will utilize the capital to expand its drug development pipeline following a recent subsidiary acquisition.
Updated on Oct. 23, 2026 in Biotech
Live Poll
Do you trust private biotech companies to successfully develop life-changing medical therapies?
Star Therapeutics has secured $200 million in a private financing round co-led by OrbiMed and Janus Henderson Investors. The capital is designated to advance the company's existing pipeline of therapies following its acquisition of Vega Therapeutics.
Why it matters
The influx of capital supports the development of Star Therapeutics' drug pipeline, which was expanded by the company's acquisition of Vega Therapeutics earlier this year. This funding round demonstrates continued investor interest in specialized biotechnology firms despite broader market fluctuations.
The company secured $200 million in private funding, a significant injection compared to its prior operational state. Further details regarding the allocation of these funds across the research pipeline are not yet public.
The players
Star Therapeutics
A biotech firm focused on building a pipeline of therapeutic candidates.
OrbiMed
A global healthcare-focused investment firm known for backing early- and late-stage biotechnology ventures.
Janus Henderson Investors
An asset management group that maintains a significant portfolio of public and private life sciences companies.
Vega Therapeutics
A specialized biotech entity acquired by Star Therapeutics in July 2026 to bolster its research capabilities.
The details
Star Therapeutics focuses on developing novel therapies, a process bolstered by its recent integration of Vega Therapeutics. The company operates by identifying and advancing specific molecular targets through a research pipeline, leveraging the resources acquired in the July 2026 merger. This funding serves as the operational mechanism to sustain these development cycles as they progress toward future clinical testing.
Timeline
July 2026: Star Therapeutics finalized the acquisition of Vega Therapeutics.
October 23, 2026: The company announced the closing of its $200 million private financing round.
The Tech Race
This financing round places Star Therapeutics among a cohort of well-capitalized private firms vying for competitive advantages in drug development. It aligns with broader trends in the 2026 biotech funding climate where firms consolidate research assets to accelerate time-to-clinic.
There is no immediate impact for the general public as the company remains in the research and development phase. Investors and industry stakeholders should monitor for future clinical trial registrations or development milestones resulting from this capital.
The takeaway
The infusion of $200 million provides Star Therapeutics the runway needed to execute on its current pipeline and integrate the assets acquired from Vega Therapeutics. Interested parties should look for upcoming announcements regarding the company's drug candidates or potential clinical trial data.
Further reading
For broader trends in private funding and asset development, see the latest updates in Biotech.
Source note: This article includes information reported by Thepharmaletter.
Live Poll
Do you trust private biotech companies to successfully develop life-changing medical therapies?
